Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review.

Autor: Tsiogkas SG; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Tsimourtou V; Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Chaidaki K; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Dardiotis E; Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Roussaki-Schulze AV; Department of Dermatology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Bogdanos DP; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece., Zafiriou E; Department of Dermatology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Jazyk: angličtina
Zdroj: The Journal of dermatology [J Dermatol] 2024 Jun; Vol. 51 (6), pp. 844-848. Date of Electronic Publication: 2024 Feb 12.
DOI: 10.1111/1346-8138.17143
Abstrakt: Biologics approved for psoriasis exhibit favorable safety profiles, and serious adverse events have rarely been reported. In this report, we present the case of a patient treated with ixekizumab, an anti-interleukin (IL)-17 agent, who 8 months later developed multiple sclerosis (MS). We also review the available literature regarding the use of anti-IL-17 agents in the context of psoriasis and pre-existing or new-onset demyelination. Eight case reports were evaluated as relevant and are presented in our report. In most of the cases secukinumab or ixekizumab administration adequately controlled both skin and pre-existing neurological clinical manifestations. However, there has been a report of MS exacerbation under secukinumab treatment and the occurrence of myelitis in a patient receiving ixekizumab. While the anti-IL-17-biologic-mediated induction of inflammatory events in the central nervous system has not been proven and a causal relationship is lacking, such a probability should be considered in extremely rare cases.
(© 2024 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)
Databáze: MEDLINE
Externí odkaz: